J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals

J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticalsПодробнее

Johnson & Johnson CFO Joseph Wolk on Q3 results: Very well-positioned into 2024 and beyondПодробнее

Johnson & Johnson CFO Joseph Wolk on Q4 earnings beatПодробнее

J&J CFO Joseph Wolk on Q2 earnings beat: Very pleased with the performance overallПодробнее

J&J CFO Joseph Wolk on Q2 earnings beat: We're in a very strong position for second half of 2023Подробнее

J&J CFO Joseph Wolk on Q4 earnings beat: Near- and long-term looks very strong at the companyПодробнее

J&J CFO on Q1 Earnings, Forecast and Product PipelineПодробнее

Johnson & Johnson shares rising as earnings report shows revenue beatПодробнее

Great scientific innovation continues to produce great financial results for our company: J&J CFOПодробнее

J&J CFO Joseph Wolk on Q1 earningsПодробнее

Johnson & Johnson reports Q3 earnings beat, raises full-year guidanceПодробнее

J&J beats on EPS, misses on sales in Q3 earnings reportПодробнее

Alcoa CEO William Oplinger talks Q4 results as stock pops on resultsПодробнее

Johnson & Johnson CFO Joseph Wolk on supply challenges of Tylenol, MotrinПодробнее

Johnson & Johnson CFO on Q3 earnings, Covid vaccine boosterПодробнее

Johnson & Johnson CFO on Q2 earnings beatПодробнее

Johnson & Johnson CFO on Q2 earnings, litigation, product pipelineПодробнее

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeПодробнее

J&J Tops 3Q Estimates, Boosts Full-Year Profit GuidanceПодробнее

Johnson & Johnson CFO on Q3 earnings, outlook and moreПодробнее